Skip to main content
Top
Published in:

09-05-2024 | Prostate Cancer | BRIEF RESEARCH ARTICLE

Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution

Authors: Javier Gavira, Jose Carlos Tapia, Alejandra Romano, Georgia Anguera, María Aguado, Aida Piedra, Freya Bosma, Sofía Sánchez, Cristina Martin, Ferran Algaba, Yolanda Arce, Teresa Ramón y Cajal, Pablo Maroto

Published in: Clinical and Translational Oncology | Issue 10/2024

Login to get access

Abstract

Purpose

We evaluated the prevalence of homologous recombination deficiencies (HRD) to determine the efficacy of different techniques and clinical characteristics of patients.

Methods

This retrospective study included patients with metastatic prostate cancer who underwent molecular testing at our hospital between 2016 and 2022. We used tumor tissue, ctDNA, and lymphocytes for somatic or germline testing. We analyzed the clinical characteristics and survival outcomes.

Results

144 patients were tested (113 somatic, 21 germline, and 10 both). Technical issues prevented the analysis of 23 prostatic samples (18.7%). 12 (8.3%) patients had HRD. BRCA2 was the most frequent mutation (66.7%). Patients with HRD were younger (57.5 years). Patients with BRCA mutations had poorer survival (31.9 vs 56.3 months, p = 0.048).

Conclusion

In our institution, 8.3% of the patients had HRD. Tumor tissue analysis failed in 18.7% of tests. ctDNA analysis is an alternative detection method. BRCA mutations are correlated with poor prognosis.
Literature
5.
11.
go back to reference Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, et al. Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status. Abstract of ASCO Congress 2023. J Clin Oncol. 2023;41(suppl 16):5003.CrossRef Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, et al. Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status. Abstract of ASCO Congress 2023. J Clin Oncol. 2023;41(suppl 16):5003.CrossRef
Metadata
Title
Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution
Authors
Javier Gavira
Jose Carlos Tapia
Alejandra Romano
Georgia Anguera
María Aguado
Aida Piedra
Freya Bosma
Sofía Sánchez
Cristina Martin
Ferran Algaba
Yolanda Arce
Teresa Ramón y Cajal
Pablo Maroto
Publication date
09-05-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 10/2024
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03483-8

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now